FDA finds falsified records, unsanitary conditions at Dabur India facility

Dabur skipped checks, US scrutiny tightens

Dabur hasn't responded yet, but these findings could mean trouble for its business in the US.
The report also pointed out that management skipped key quality checks and reused equipment meant for specific products, which breaks important safety rules.
This comes as Indian pharmaceutical exporters face tighter scrutiny from US regulators, so all eyes are on how Dabur will handle it.